Protalix BioTherapeutics, Inc.
PLX
$2.22
-$0.14-5.93%
AMEX
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 19.90M | 33.75M | 9.12M | 17.85M | 15.66M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 19.90M | 33.75M | 9.12M | 17.85M | 15.66M |
| Cost of Revenue | 7.76M | 4.13M | 23.51M | 8.32M | 5.87M |
| Gross Profit | 12.13M | 29.62M | -14.39M | 9.53M | 9.79M |
| SG&A Expenses | 3.11M | 3.05M | 3.53M | 2.93M | 2.62M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 15.22M | 12.60M | 13.78M | 15.72M | 14.49M |
| Operating Income | 4.67M | 21.15M | -4.66M | 2.13M | 1.17M |
| Income Before Tax | 4.86M | 21.14M | -4.78M | 2.24M | 661.00K |
| Income Tax Expenses | 1.08M | 2.82M | 728.00K | -116.00K | 497.00K |
| Earnings from Continuing Operations | 3.78M | 18.32M | -5.50M | 2.36M | 164.00K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 3.78M | 18.32M | -5.50M | 2.36M | 164.00K |
| EBIT | 4.67M | 21.15M | -4.66M | 2.13M | 1.17M |
| EBITDA | 5.08M | 21.55M | -4.27M | 2.50M | 1.53M |
| EPS Basic | 0.05 | 0.23 | -0.07 | 0.03 | 0.00 |
| Normalized Basic EPS | 0.04 | 0.17 | -0.04 | 0.02 | 0.01 |
| EPS Diluted | 0.05 | 0.22 | -0.07 | 0.03 | 0.00 |
| Normalized Diluted EPS | 0.04 | 0.16 | -0.04 | 0.02 | 0.01 |
| Average Basic Shares Outstanding | 79.99M | 79.85M | 79.51M | 79.28M | 78.66M |
| Average Diluted Shares Outstanding | 82.56M | 83.05M | 79.51M | 80.81M | 81.27M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |